This is the most consequential item in rare disease this week and it is not a drug. Two design features do the damage. First, the exemption is keyed to functional interference rather than diagnosis, which inverts the burden for episodic and relapsing conditions where a patient works one month and cannot the next. Second, with no federal definition, someone can be medically frail in Nebraska and not in Delaware, as NORD’s Carolyn Sheridan has put it. States face financial penalties for granting exemptions incorrectly and none for denying them, so the incentive runs in one direction only.

• The undiagnosed are the most exposed group. Roughly one in ten Americans has a rare disease and many never receive a clean ICD code. An exemption process built around documented conditions has no mechanism for someone four years into a diagnostic odyssey.
• For manufacturers, model this as coverage continuity risk, not pricing risk. Rare disease revenue depends on uninterrupted authorisation, and a lapse of even a few weeks breaks specialty pharmacy fills, infusion scheduling and prior authorisation status that then has to be rebuilt from scratch.
• Resource patient services now, not in January. Reverification support, state-by-state exemption documentation and proactive outreach in expansion states are the practical response. A Yale analysis found more than 40% of the roughly five million people at risk of disenrollment carry at least three chronic conditions.

The competitive consequence landed the same day: Omeros shares rose on the readout, because a failed adult Ultomiris trial removes the most credible challenger to narsoplimab in transplant-associated TMA. That is the story in one line. A complement inhibitor with an established franchise and a global sales force failing a randomised endpoint hands formulary position and pricing latitude straight back to the incumbent.

• The paediatric path stays open but is structurally weaker. Filing on a single-arm study plus real-world evidence, immediately after a randomised failure in adults, invites a harder review and a narrower label. Payers will read the adult miss into their paediatric coverage policy whether or not the agency does.
• Portfolio context for AstraZeneca: this follows the anselamimab misses in light chain amyloidosis. The Alexion rare disease engine has now delivered two randomised disappointments against a corporate target of $80 billion in revenue by 2030 built on roughly twenty launches.
• Watch for a subgroup or endpoint pivot in adults. A trend toward benefit on event-free survival is the language of a sponsor preparing a post-hoc case. The deramiocel adcomm the same week is a live illustration of how those cases are now received.

The disclosure that matters is the surrogate, not the filing date. Written FDA acceptance of SVR35 as a reasonably likely surrogate endpoint is a precedent every myelofibrosis developer will now cite, because it converts a 24-week imaging endpoint into an approvable one and lifts the multi-year survival wait off the critical path. If it holds, the barrier to entry in this indication just fell for the whole field, not only for Karyopharm.

• The confirmatory design is unusually disciplined. SENTRY has no crossover provision and stays blinded through follow-up, which preserves the integrity of the overall survival analysis. That is the strongest argument Karyopharm has that verification will actually be deliverable, and it is exactly what accelerated approval reform has been asking sponsors to do.
• Read the filing as a financing event as much as a regulatory one. Karyopharm disclosed in the same window that its Phase 3 XPORT-EC-042 in endometrial cancer missed on progression-free survival, and that it is exploring financing transactions and strategic alternatives with advisers including Centerview Partners. An August sNDA with Priority Review is the cleanest value inflection it can put in front of a counterparty.
• Competitive frame: every approved myelofibrosis therapy to date is a JAK inhibitor. Selinexor inhibits XPO1, so this would be the first approved combination adding a genuinely new class, and the JAKi-naive, platelet-above-100 positioning stakes out a front-line segment rather than salvage.

The structural novelty here is the handoff. n-Lorem exists to make antisense medicines charitably for conditions affecting roughly thirty people or fewer, a population no commercial model reaches. When a programme turns out to be larger than that, the foundation looks for a partner, and Stanley Crooke has now formalised that graduation path with a major rare disease company. This is a new supply route into rare disease pipelines: nonprofit discovery de-risks the biology, a commercial partner carries it through IND and approval.

• The economics work because of variant concentration. A single recurrent insertion covering roughly three quarters of cases turns an ultra-rare indication into a one-ASO, one-diagnostic problem rather than a family of bespoke medicines. That is precisely the difference between a charitable programme and a licensable asset.
• Two years from gene discovery to a licensed development programme is fast even by current standards, and it is a direct consequence of population-scale sequencing finding the gene at all. Expect more of these. The rate-limiting step in ultra-rare has moved from discovery to development capital.
• What cannot be benchmarked yet: no terms, no named candidate, and no disclosed ASO mechanism. Normal for pre-IND, but it means anyone modelling BioMarin’s genetic medicines pipeline should carry this as optionality rather than value.

Platform reuse is the whole argument. A delivery chassis with two programmes already in clinic lets Dyne enter a third indication with known biodistribution and a known safety frame, which is why this Phase 1 can open at 1.5 mg/kg with a 96-week extension attached rather than crawling up from a token dose. That is real time saved.

• But the field filled in during the build. Fulcrum’s losmapimod failed and the programme was suspended in 2024. Since then Avidity, Epicrispr, Altay (whose oral DUX4 inhibitor holds orphan status), Sarepta and Scholar Rock have all taken positions, and four of them joined the FSHD Industry Collaborative this same week. Third on a platform is not the same as first in an indication.
• The endpoint is the real gate, and Dyne does not control it. FSHD has no accepted regulatory endpoint, which is exactly what the Collaborative is pooling biomarker, natural history and MRI analytics data to fix. Whoever reads out first will be judged against measures that do not yet exist in final form.
• Note the shared target. DYNE-302 uses transferrin receptor 1 for delivery, and Apertura’s TfR1 CapX capsid in the TSC programme below uses the same receptor for AAV. TfR1 is quietly becoming the standard access route into muscle and brain, which concentrates a lot of the field’s delivery risk in one piece of biology.

The option structure is the interesting part, not the headline number. Nippon Shinyaku paid for the right to wait, watched a pivotal Phase 3 complete, and only then wrote the cheque. For an ultra-rare paediatric indication with no approved comparator, that is a rational way to buy a commercial asset without funding the clinical risk, and it is a template smaller rare disease companies should expect to be offered rather than to negotiate away.

• The rights split is unusually favourable to the originator. Keeping ex-US rights and every other US indication means the IL-18 platform stays with AB2 Bio while a partner with existing US rare disease commercial infrastructure carries the launch. NS Pharma already runs a US neuromuscular operation, so the channel exists rather than needing to be built.
• Competitive context worth holding: IL-18 is getting busy. Evommune’s EVO301, an IL-18 binding protein fusion, has positive Phase 2a proof of concept in atopic dermatitis with ulcerative colitis planning underway. Tadekinig alfa is a recombinant IL-18BP, so the mechanism is being validated in indications orders of magnitude larger than NLRC4 and XIAP.
• The ratio tells you where both parties think risk sits. $600 million of milestones against a $30 million upfront is roughly twenty to one, which prices the remaining risk as approval and uptake rather than biology.

Overenrolment by roughly 17% in an ultra-rare indication is a genuine signal about unmet need and site availability. It is also the cheapest form of good news a sponsor can report. Treat it as evidence that the trial can be run, not as evidence the drug works.

• The mechanism is sound and it is not novel. ANGPTL3 inhibition lowers LDL cholesterol independently of the LDL receptor, which is precisely why Regeneron’s evinacumab is already approved in HoFH. Zodasiran’s differentiation is therefore administration and durability, not mechanism: infrequent subcutaneous RNAi against a regularly infused intravenous antibody.
• That makes this a market access contest more than a clinical one. In an ultra-rare, paediatric-onset condition managed at lipid specialist centres, removing infusion-centre dependence is a real argument, but it will be priced against an incumbent with years of data and settled coverage policy.
• Timeline discipline: mid-2027 completion means filings in 2028 at the earliest, by which point other LDL-receptor-independent approaches will also have read out. Enrolment completion de-risks execution. It does not accelerate anything.

Timing precision is what makes a prevention trial financeable in a rare disease. A prevention study in genetically at-risk carriers currently has to enrol broadly and wait. A panel that brackets onset to plus or minus 18 months lets a sponsor enrich for imminent converters, shrink the sample and shorten follow-up. That is the manoeuvre that made pre-symptomatic Alzheimer’s trials viable, imported into a population two orders of magnitude smaller.

• Direct beneficiaries are the genetically defined ALS programmes. Biogen’s tofersen already runs ATLAS in pre-symptomatic SOD1 carriers with NfL-triggered initiation, so this panel is a refinement of exactly that trigger logic. It is equally relevant to FUS-targeted antisense and to any C9orf72 programme contemplating a prevention design.
• Hold the caveats firmly. Thirty-three converters is a small denominator, the cohort is familial, and transfer to sporadic ALS, roughly 90% of cases, is unproven. There is no analytical validation, no CLIA assay and no regulatory qualification. This is a research signature, not a test.
• The corollary is a rare disease problem in miniature. A predictive panel in an untreatable condition creates a genetic counselling and disclosure burden before it creates a therapeutic option, and no reimbursement pathway currently funds that counselling.

For commercial teams this is a target list, not a press release. A designated centre network is where diagnosis concentrates, where trial referrals originate and where launch-phase prescribing begins, and it now covers 28 states with a named director at every site. Field medical and patient services planning should map to it directly.

• The timing sits awkwardly against the Medicaid item above. NORD is building referral infrastructure in the same month that coverage continuity for the patients who would use it becomes conditional on paperwork. Expertise concentrated in 49 centres does not help a patient who has lost the coverage needed to reach one.
• The Northwell designation is specifically a Rare Diagnosis Center of Excellence, under Ian Krantz. Shortening the diagnostic odyssey is becoming its own designated function rather than a byproduct of specialist care, which is the right structural response to the undiagnosed population.
• The network reaches its fifth anniversary in November. Expect outcome data around that milestone. Whether designation actually shortens time to diagnosis is the question that determines whether this is infrastructure or branding.

This is a de-escalation study that failed cleanly, and the field needed it. Venetoclax plus azacitidine causes prolonged cytopenias, and more than half of patients in VIALE-A had dose interruptions or shortened schedules, so 14-day dosing had already drifted into routine practice supported largely by retrospective series. A randomised comparison that does not confirm non-inferiority pulls that practice back toward the label.

• The mutation-dependent finding is the durable result. If NPM1 and IDH2 patients specifically require the full 28 days, venetoclax duration becomes a genotype-directed decision rather than a tolerability-directed one, which means molecular results have to arrive before the dosing decision rather than after it.
• Note who ran it. This is a master protocol run by a patient organisation answering a question no manufacturer had commercial reason to ask. Optimising the dose of an approved combination generates no new revenue, which is exactly why non-industry trial infrastructure matters in rare oncology.
• Practical read for payers and pathway committees: 14-day dosing should not be defaulted to on cost or toxicity grounds without mutation status, and any pathway rule written before this readout needs revisiting.